Abstract
Survival is considered an important indicator of the quality of cancer care, but the validity of different methodologies to measure comparative survival rates is less well understood. We explored whether the National Cancer Data Base (NCDB) could serve as a source of unadjusted and risk-adjusted cancer survival data and whether these data could be used as quality indicators for individual hospitals or in the aggregate by hospital type. The NCDB, an aggregate of > 1,500 hospital cancer registries, was queried to analyze unadjusted and risk-adjusted hazards of death for patients with stage III breast cancer (n = 116,787) and stage IIIB or IV non-small-cell lung cancer (n = 252,392). Data were analyzed at the individual hospital level and by hospital type. At the hospital level, after risk adjustment, few hospitals had comparative risk-adjusted survival rates that were statistically better or worse. By hospital type, National Cancer Institute-designated comprehensive cancer centers had risk-adjusted survival ratios that were statistically significantly better than those of academic cancer centers and community hospitals. Using the NCDB as the data source, survival rates for patients with stage III breast cancer and stage IIIB or I...Continue Reading
References
Apr 12, 2002·The New England Journal of Medicine·John D BirkmeyerDavid E Wennberg
Jun 24, 2004·Statistics in Medicine·Michael J Pencina, Ralph B D'Agostino
Apr 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joseph O JacobsonJoseph V Simone
Dec 15, 2010·The New England Journal of Medicine·Michael E Porter
Nov 1, 2009·Journal of Oncology Practice·Douglas W BlayneyMary Malloy
Jun 3, 2011·The New England Journal of Medicine·Jonathan F FinksJohn D Birkmeyer
Sep 17, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Douglas W BlayneyJoseph Simone
Apr 30, 2015·Gynecologic Oncology·David I ShalowitzRobert L Giuntoli
Oct 9, 2015·The New England Journal of Medicine·David R Urbach
Oct 9, 2015·JAMA Oncology·David G PfisterPeter B Bach
Apr 7, 2016·The New England Journal of Medicine·Andrea L MerrillJustin B Dimick
Sep 7, 2016·The Lancet Oncology·David Cameron
Sep 7, 2016·The Lancet Oncology·Melanie MorrisMichel P Coleman
Sep 7, 2016·The Lancet Oncology·Michael WallingtonDavid Dodwell
Citations
Mar 9, 2018·Annals of Surgical Oncology·Lucy M De La Cruz, Lawrence N Shulman
Aug 22, 2018·Journal of Surgical Oncology·Jason B LiuSharon M Weber
May 18, 2019·American Society of Clinical Oncology Educational Book·Gabrielle Betty RocquePeter Paul Yu
Dec 7, 2017·Journal of Oncology Practice·Debra Patt, Ray Page
Aug 25, 2019·BMJ Quality & Safety·Christopher ManzJustin Bekelman
Jan 27, 2019·Annals of Surgical Oncology·Megan E MillerKatharine A Yao
Mar 31, 2019·Annals of Surgical Oncology·Lawrence N ShulmanDaniel P McKellar
Nov 28, 2019·International Journal of Particle Therapy·Amy C MorenoSteven H Lin
Jun 20, 2019·Annals of Surgical Oncology·Lawrence N Shulman
May 27, 2020·JAMA Network Open·Daniel J BoffaLawrence N Shulman
Jun 25, 2020·Langenbeck's Archives of Surgery·Manuel Bellver OliverLuis Sabater-Ortí
Jul 28, 2020·Annals of Surgical Oncology·Thomas C TuckerTimothy W Mullett
Mar 23, 2021·JAMA Network Open·Nancy L KeatingMary Beth Landrum
May 5, 2021·Cancer Medicine·Daniel P NussbaumDan G Blazer
Jul 10, 2021·JAMA Network Open·Zachary A K FroschSamuel U Takvorian
Aug 4, 2021·JAMA Network Open·Samuel U TakvorianJustin E Bekelman
Aug 4, 2021·JAMA Network Open·Nancy L Keating
Jul 22, 2021·The Oncologist·Marija IvanovićTanja Cufer
Sep 22, 2021·The Annals of Thoracic Surgery·Richard ZhengTyler Ross Grenda